AIDS Therapies

Patient Subset Indicates Remune and Antiviral Drugs May Stimulate 'Killer' T-Cell Activity

Published in AIDS Weekly, July 3rd, 2000

The Immune Response Corp. (IMNR), Carlsbad, California, announced preliminary interim clinical results that indicate Remune (HIV-1 Immunogen) may stimulate cytotoxic T lymphocytes (CTL) or "killer" T-cell activity specifically against HIV in people infected with HIV concurrently on antiviral drug therapy (ART).

These data represent two-year immunological results from a Phase II clinical trial of Remune, an investigational product, currently being tested in Spain (STIR-2102). These data were presented on June 18 at the Fifth European Conference on Experimental AIDS Research (ECEAR) 2000 in Madrid, Spain. CTLs are white blood cells of the immune system (CD8 lymphocytes)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-07-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry